0001558370-24-000128.txt : 20240108 0001558370-24-000128.hdr.sgml : 20240108 20240108083012 ACCESSION NUMBER: 0001558370-24-000128 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240108 DATE AS OF CHANGE: 20240108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 24518485 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 8-K 1 hrmy-20240108x8k.htm 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 8, 2024

HARMONY BIOSCIENCES HOLDINGS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-39450	82-2279923
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

630 W. Germantown Pike, Suite 215

Plymouth Meeting, PA 19462

(Address of principal executive offices) (Zip Code)

(484) 539-9800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, $0.00001 par value per share	HRMY	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 8, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2023. In addition, the Company provided guidance related to 2024 net product revenue and disclosed the number of shares repurchased during the fourth quarter and year ended December 31, 2023. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Note Regarding Forward-Looking Statements

Certain statements in this Current Report on Form 8-K constitute “forward-looking statements” within the meaning of the federal securities laws. These statements are based on management’s current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission (“SEC,”) on February 21, 2023, as well as other factors described from time to time in the Company’s filings with the SEC. Such forward-looking statements are made only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statement because of new information, future events or otherwise, except as otherwise required by law. If it does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.


Exhibit
No.		Description

99.1*		Press release issued by the Company, dated January 8, 2024.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

This Exhibit is furnished herewith and will not be deemed “filed” for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	HARMONY BIOSCIENCES HOLDINGS, INC.

Date: January 8, 2024	By:	/s/ Sandip Kapadia
		Sandip Kapadia
		Chief Financial Officer and Chief Administrative Officer

EX-99.1 2 hrmy-20240108xex99d1.htm EX-99.1

‌Exhibit 99.1

HARMONY BIOSCIENCES PRELIMINARY UNAUDITED FOURTH QUARTER AND FULL YEAR 2023 NET PRODUCT REVENUE INCREASES MORE THAN 30 PERCENT; PROVIDES 2024 NET PRODUCT REVENUE GUIDANCE

WAKIX® (pitolisant) Preliminary Net Revenue of ~$168 Million for Fourth Quarter and ~$582 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively

Average Number of Patients on WAKIX Increased to ~6,150

2024 Net Product Revenue Projected Between $700 -$720 Million

$50 Million Common Stock Repurchase in Fourth Quarter Bringing 2023 Total to $100 Million; Expect to Continue Opportunistic Share Repurchases in 2024

PLYMOUTH MEETING, PA., Jan. 8, 2024 — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported preliminary, unaudited fourth quarter and full year 2023 net product revenue growth of more than 30 percent.

The company also provided 2024 net product revenue guidance of $700 to $720 million and outlined key priorities in advance of its presentation at the 42^nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 5:15 p.m. PT / 8:15 p.m. ET.

"In 2023, Harmony advanced our clinical development programs and diversified our portfolio while achieving net revenue of approximately $582 million," said Jeffrey M. Dayno, M.D., Harmony President and CEO. "We enter 2024 poised to generate up to $720 million in net revenue and are well on our way toward a one billion dollar plus opportunity for WAKIX in adult narcolepsy alone. Leveraging our strong cash position, as well as our expertise in clinical development and commercial execution, we will continue to advance our growth strategy by adding new products to build out a robust pipeline.”

Fourth Quarter and Full Year 2023 Net Product Revenue (Preliminary and Unaudited)

●

Preliminary, unaudited net product revenue for the quarter ended December 31, 2023, was approximately $168 million, compared to $128.3 million for the same period in 2022, representing ~31% growth

●

Preliminary, unaudited net product revenue for the full year ended December 31, 2023, was approximately $582 million, compared to $437.9 million for the same period in 2022, representing ~33% growth

●

The average number of patients on WAKIX increased by approximately 350 sequentially to approximately 6,150 for the quarter ended December 31, 2023

2024 Key Priorities

●

Continued Strong Growth for WAKIX in Adult Narcolepsy

o

Drive commercial strategy to achieve Net Revenue >$700 million

o

Grow average number of patients on WAKIX to ~7,000

o

Increase educational outreach to drive continued growth in depth and breadth of prescriber base and patient interest in WAKIX

●

Advance and Expand the Pipeline

o

Report pharmacokinetic (PK) data on new pitolisant-based formulations in 1H 2024

o

Drive patient enrollment in the Phase 3 pivotal RECONNECT trial for Fragile X syndrome

o

Initiate Phase 3 TEMPO study in Prader-Willi syndrome in Q1 2024

o

FDA meeting request submitted to discuss Idiopathic Hypersomnia path forward; anticipate meeting in Q1 2024

o

Complete review of positive Myotonic Dystrophy Type 1 Phase 2 POC data in EDS and fatigue; assess opportunity

●

Disciplined Capital Allocation to Maximize Shareholder Value

o

Actively pursue business development opportunities to expand our pipeline and diversify our portfolio

o

Continued opportunistic execution of share repurchase program

2024 Net Product Revenue Guidance

●

Expect full year 2024 net product revenue of $700 million to $720 million

Share Repurchase Program

●

Repurchased ~1.8 million shares of common stock for $50 million in fourth quarter 2023

●

Repurchased ~3.2 million shares of common stock for $100 million in full year 2023

●

Remaining share repurchase program authorization of $150 million. Expect to continue opportunistic repurchase of shares.

The financial information included in this press release is preliminary, unaudited, and subject to change. It does not present all the information necessary for an understanding of the company’s financial results for the fourth quarter or full year 2023.

About WAKIX® (pitolisant) Tablets

WAKIX, a first-in-class medication, is approved by the U.S. Food and Drug Administration for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy and has been commercially available in the U.S. since Q4 2019. It was granted orphan drug designation for the treatment of narcolepsy in 2010, and breakthrough therapy designation for the treatment of cataplexy in 2018. WAKIX is a selective histamine 3 (H₃) receptor antagonist/inverse agonist. The mechanism of action of WAKIX is unclear; however, its efficacy could be mediated through its activity at H₃ receptors, thereby increasing the synthesis and release of histamine, a wake promoting neurotransmitter. WAKIX was designed and developed by Bioprojet (France). Harmony has an exclusive license from Bioprojet to develop, manufacture and commercialize pitolisant in the United States.

Indications and Usage

WAKIX is indicated for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy.

Important Safety Information

Contraindications

WAKIX is contraindicated in patients with known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported. WAKIX is also contraindicated in patients with severe hepatic impairment.

Warnings and Precautions

WAKIX prolongs the QT interval; avoid use of WAKIX in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval. Avoid use in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval.

The risk of QT prolongation may be greater in patients with hepatic or renal impairment due to higher concentrations of pitolisant; monitor these patients for increased QTc. Dosage modification is recommended in patients with moderate hepatic impairment and moderate or severe renal impairment (see full prescribing information). WAKIX is not recommended in patients with end-stage renal disease (ESRD).

Adverse Reactions

In the placebo-controlled clinical trials conducted in patients with narcolepsy with or without cataplexy, the most common adverse reactions (≥5% and at least twice placebo) for WAKIX were insomnia (6%), nausea (6%), and anxiety (5%). Other adverse reactions that occurred at ≥2% and more frequently than in patients treated with placebo included headache, upper respiratory tract infection, musculoskeletal pain, heart rate increased, hallucinations, irritability, abdominal pain, sleep disturbance, decreased appetite, cataplexy, dry mouth, and rash.

Drug Interactions

Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant exposure by 2.2-fold. Reduce the dose of WAKIX by half.

Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant by 50%. Dosage adjustments may be required (see full prescribing information).

H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX. Patients should avoid centrally acting H1 receptor antagonists.

WAKIX is a borderline/weak inducer of CYP3A4. Therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX. The effectiveness of hormonal contraceptives may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy.

Use in Specific Populations

WAKIX may reduce the effectiveness of hormonal contraceptives. Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with WAKIX and for at least 21 days after discontinuing treatment.

There is a pregnancy exposure registry that monitors pregnancy outcomes in women who are exposed to WAKIX during pregnancy. Patients should be encouraged to enroll in the WAKIX pregnancy registry if they become pregnant. To enroll or obtain information from the registry, patients can call 1-800-833-7460. The safety and effectiveness of WAKIX have not been established in patients less than 18 years of age.

WAKIX is extensively metabolized by the liver. WAKIX is contraindicated in patients with severe hepatic impairment. Dosage adjustment is required in patients with moderate hepatic impairment.

WAKIX is not recommended in patients with end-stage renal disease. Dosage adjustment of WAKIX is recommended in patients with moderate or severe renal impairment.

Dosage reduction is recommended in patients known to be poor CYP2D6 metabolizers; these patients have higher concentrations of WAKIX than normal CYP2D6 metabolizers.

Please see the Full Prescribing Information for WAKIX for more information.

To report suspected adverse reactions, contact Harmony Biosciences at 1-800-833-7460 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

About Harmony Biosciences

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our product WAKIX and our future capabilities following the acquisition of Zynerba. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of WAKIX, pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved; our research and development plans, including our development activities with Bioprojet, and plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; the availability of favorable insurance coverage and reimbursement for WAKIX; the timing of and our ability to obtain regulatory approvals for pitolisant for other indications as well as any of our product candidates, including those we are developing with Bioprojet; our failure to achieve the potential benefits of the 2022 LCA with Bioprojet; our ability to recognize the intended benefits of our acquisition of Zynerba Pharmaceuticals; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and

manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony’s common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe and the significant costs and required management time as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 21, 2023, and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Harmony Biosciences Investor Contact:

Luis Sanay, CFA

445-235-8386
lsanay@harmonybiosciences.com

Harmony Biosciences Media Contact:

Cate McCanless

202-641-6086

cmccanless@harmonybiosciences.com

GRAPHIC 3 hrmy-20240108x8k001.jpg GRAPHIC begin 644 hrmy-20240108x8k001.jpg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end GRAPHIC 4 hrmy-20240108xex99d1001.jpg GRAPHIC begin 644 hrmy-20240108xex99d1001.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" "N ,,# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBL?Q3XOT;P1I+ZIK^IVVD::C*C75W($C!8X R?4T ;%%>9_\-+_"K_H?] _\ M#4_QH/[2_P *O^B@:!_X&I_C0!Z916?H&OZ=XIT>UU;2;V'4=-ND\R"ZMW#Q MR+G&5(ZCBM"@ HHHH ***0T +16._B[1HG9'U*W5E)!!<9!':FGQIH0ZZK:C M_MH*Y/KF&V]I'[T!M45AGQOH ZZO:#_MH*:?'?AX==8L_P#OZ*?UO#_\_%]Z M%==S>HK _P"$^\.Y _MFSS_UU%7H/$>E7,@2'4[25R,A4G4D_AFKC7I2^&2? MS0N:/O>Z9D%%%% "& MO,OAEXW;7?B1\3/#TLQ>;1-2@"(TN2(Y;>-QA?X1DL/?!KTZOC+X3>-FTG_@ MH[\7O##28AU;2+.Z5 @.7A1 26ZCB3I0!VWQ+T_^S/&NJQ8(5Y/.7/<,,_SS M^5<=,1BO4OC]8?9M=T^]50!<0&-B!U93W/T/Z5YUI'AW5/$K3+IEG)>&( N$ MQ\N>E?S%FV75*6;U\/2BVW)M):Z/4YJDKNQAS8S5*8#!XKM)/A;XL;IHEP?R M_P :K2_"?Q>>FA7!_%?\:UIY7CE_RYE_X"SS:D)OH<-<<*:P;V1HF+([(?56 M(->EW7PD\8A&(T"Y('/&/\:X#Q+XC30LH_,BO6I8/$T?>J M4Y+U31X>*A.,;N+%\/\ QD\7>"+A7T_6)GA!YMKD^9&P';!^G:OIOX,?M*Z/ M\2Y$TK45CTCQ >%MRW[NX]XR>_\ LGFOBN_DZ\U@-J5QI=[#>6DS6]W;N)(I M4X*,.017VV69A7P[2;O'L_T/#I9Q7P,T[WCU3_3L?JT#FEKSGX!_$U?BK\.= M/U:1@=00?9[Q0,8E7@G\>OXUZ-7Z3"2G%2CLS]-HU85Z<:L'=-7044459L%% M%% !1110 5\D_P#!4/\ Y-+UK_L(6/\ Z/6OK:ODG_@J)_R:7K7_ &$++_T> MM UN?C%128]A1CV%(T/W9_8-_P"3/_A9_P!@A?\ T8]>]UX)^P;_ ,F?_"S_ M +!"_P#HQZ][IF04444 %?EIX_\ &W_" _\ !6*PU!W6."YO+73I6MPJCAOO1AU&[H>O6N _9G??=ZW_N1_S-?GN,POL^),/72^)/[TFORL M<<]*T?,]YHI*,5^@G6%5K^PMM4M7MKR".ZMW&&CE0,I'T-6>M)0TGHQ/4^"/ MVE/A];?#CQZUO8#9IE_#]KMXLY\ODAE^@(X]C[5X;J$O6OH3]LCQ?8:_\2;: MRLI1,VE6GV:XD4Y7S&8L5'N!@'W^E?-M_-G-?G=>C".*FJ>U_P"OQ/Q/.Y4X M8JI&GM?_ (<^L?V ?$#&[\6Z,\PV?NKJ.'ODY5C^@K[(KXE_X)]Z$\^O^+-: M97$<4,5HK<;222Q'U''YU]M5]O@DUAXIGZ+PU*4LLIN7G]UV%%%%=Q]0%%%% M !1110 5\D_\%0_^32]:_P"PA8_^CUKZVKY)_P""H?\ R:7K7_80LO\ T>E M+<_&*BDP*,"D:GU9\)_^"D/Q/^#GPZT'P7HFE>&9])T:W%M;R7MI.\S+DGYB MLR@GD] *ZS_A[9\9/^@)X/\ _ *X_P#C]?$^!1@4"LC[8_X>V?&3_H">#_\ MP"N/_C]'_#VSXR?] 3P?_P" 5Q_\?KXGP*,"@+(^V/\ A[9\9/\ H">#_P#P M"N/_ (_7R_\ &?XNZS\=/B'J7C/Q!!9V^JZ@(Q+'IZ,D(V(%& S,>@'>N'P* M,4!8_<3_ ()_>,U^('[(7@>$9)1YFGZC%J,$9+S@!+J""X7G/7(/\ *O(QF']IBL/67V6_QBSCJK]Y M!^?Z'2_$'Q'/X1\&:KK%O&DL]I%YB)+G:3D#G'UKYSN?VL_$JCY--TQ3ZE7/ M_LU>X_'=_+^$?B=O2V'_ *&M?!%S?9'6OGL]Q>*P^(A&A-Q373U9\]F^-JX6 MI&-.5KH]PNOVO?&"']W9:2H]X7/_ +/7$^-OVGO'7BFSDM#J,6EVLBE)$TZ+ MRV8$8.7)+#.>Q%>775[[UBWEWUYKR*>+QE5\?LS?M+^ M&?A;M>'K>S2X(5]M?]A"Q_P#1ZU];5\D_\%1/^32]:_["%C_Z/6@:W/QB MHHQ1CVI&A]D_!G_@F?XJ^-'PM\-^-[#Q=IEA::W:BZCMI[9V>,;B,$@X/2NS M_P"'0'C;_H>M&_\ 23_ .*K[<_8-_Y,_P#A9_V"%_\ 1CU[W3(NS\J/^'0' MC;_H>M&_\!)/_BJ/^'0'C;_H>M&_\!)/_BJ_5>B@+L_*C_AT!XV_Z'K1O_ 2 M3_XJOD3X\_!Z]^ OQ0U7P3J%_#J=WIXC+W5NA1&WH&& ?3-?T)5^(?\ P4;' M_&7?C/\ W+7_ -$)0-,[7_@E/XT/A[]I2XT5G98->TF: J" IDB(E0G/LK@8 M[M7Z\1Z5&FL2:B"?->$0D=L YK\!_P!F;QDOP^_: \ Z^[K'%:ZO )6=2P$; MMLB6,D45W>P^7&\Q(0'<#SCZ5\L' M]C3QK(<-JFDJ/4,Y_I7VE17GXG+Z&+FIU5=K0\K%Y;A\;)2K)W6FY\52?L1^ M+9(R3KNF*_IM?%<]JG[$/Q CMI9(+W2+J11E85E=2WXE<"OO:DK%95A8[1_$ M\J?#>7U%9Q?WL_(CXC>!?$?PUU8Z;XDTJ?3+ALF-G&8Y@.I1QPPY'3UYKA9Y M]Q-?IM^VUX6M?$'P"UN[FBC:[TMH[RWE*)O"WQH\%ZC!O+IJL$3*C["RR,(V&?3#5^R:G@5ZF'E>%GT M/U#A3%SQ&!]E4=W!V^70=11174?:A1110 4444 %?)/_ 5#_P"32]:_["%C M_P"CUKZVKY)_X*A_\FEZU_V$+'_T>M +<_&*BBB@U/W8_8-_Y,_^%G_8('_H MQZ][KP3]@W_DS_X6?]@@?^C'KWN@R"BBB@ K\0_^"C?_ "=WXS_W+7_T0E?M MY7XA_P#!1O\ Y.[\9_[EK_Z(2@J.Y\UP7#VD\4\3,DD3B164X((.00:_H:^" MOBY?'GPC\'^(%<.=0TNWF9@^_P"?8 V3W.0<^]?SQ$9%?M'_ ,$SO&K^+OV6 MM&M)9&>71;F?3SN "AMR@8[8:@\9H46\8@1M\RC\C7GK_&?QO_T-FK_^!;?XUPO%*+:<3\XK<94:%65&="5X MMK==#]B*CGN8K:,R32)$@Y+.P4#\37XZ/\:/''_0VZO_ .!;?XUDZU\3O%6N M0"#4/$>IWD(.0DMTY'IZT?6D^AG_ *Z46O=HN_JC[-_;F_:/\/:CX-E\!^'M M0@U6]NIT.H2P'>D$:$,%W#@L6"].P-?!$\_O4^'OB)I']J>&=8M-;T[>8_M-G)O3<.HSZT ;]?)/_ 5$ M./V2]:_["%C_ .CUKZD\1>(M,\):)>:QK-]#INEV<9EN+NX;;'$OJQ["N/L= M=^&O[17A^_L+:ZT7QUHT$L?VJW^6XA1_O)N!XSQD?2@#^>W>/4?G1N'J/SK] M_I?V7?@Y!$\DGPW\,(B LS'38L #J>E<)X7\*?LM^-?$*:%H.C^ M5UAPY6R MMK:%Y#M^]@8[4%\QK?L&?\F?_"S_ +! _P#1CU[W6;X=\.:7X2T6TT?1;"WT MO2[1/+M[.UC$<42YSA5' '-AQ00=Y17DQ_:P^#H'_ "4;P_\ ^!:UZ%X9\6Z+XSTR/4="U6TU>Q< K/9S M+(O(R.0>.* ->OQ"_P""C; ?M=^,^?X+7_T0E?L9XZ^,'@KX8SVL/BOQ-IV@ M2W2EX$OIA&9 .I&>N*P[KX0?"CXMR)XKN?"GASQ0^HQK(NJR6D.%67Q]X1DDB!;R=1B7G><91O;'(K[9F_9>^#=M M"\LOPX\+QQ(I9G;3H@% ZDG%8?PEUG]G_3_%KV7PYF$VOB*Y1HFBT58TFD1 M3DK\HY (H&W<^5_^"B7AK^Q?BOI6M*NV+5; !CD8+QG:>.O3;UKY.>Y'K7[2 M^,_ _A7QA;Q/XHT;3M4@M,NCZA$KK$#U(+=*^=?%7Q+_ &2O!NHK8ZE+X-%T M7:,I!;)+L93@ABH('-<4\/SR,Q<\13J)*3O:Q^;DET#WJM)<9/ M'/TK]Z\+Z)X1UV!#AFLH8GVGW Y%=#?> /A9\+-'OM9R0X.J)ZU5]S/R!\.^"/$WC2\2VT' M0-2UB9\$+9VSR<$X!R!@#/<\5]7_ )_X)U:[KE]!JGQ,D&CZ2N'&CVLH:YG M[X=UR(QZ@9/TK[S\ ^*?"_B_P[#?^$+_ $[4=%!:*.73"IB!4X*C;P,'M6CX MD\3Z5X.T2ZU?6[^#3-+M5WSW=R^V.,=,D]JVC1C'<]_!\,87#R4ZKYVODA^@ M:!IWA?1[32M*M(K#3K2,106\*[511T %:-<-;?&_P%>^#KCQ9!XKTR;PW;2^ M3-JB3@P1OG&TMV.2*T/ OQ1$?$VWNI_"GB'3]?BM7$<[6,PD\MB,@''3(KH M/L4DE9'4T5%=745E;RSSR+#!$I=Y'.%50,DD^E:X-&\.^+]*U MG5"K/]ELYQ(^U>IP.PH&=YFBC%% 'RU_P4Q4-^R#XL! (\^SX/\ U\)7,_\ M!*90O[,C8 _M:XZ?A73_P#!2_\ Y-"\6?\ 7>S_ /2A*_/?]F_X0_M,^-OA M]_:/PFUV_P!.\+_:73R;;Q +)?-&-Q\O^?\% /CBWP4 M_9\U9[&X6'7-;_XEEESAEWCYW'T7/YU^4>@^&/&?[-#Y]=@TSP=H-PFFSW\\F(8F)S<2 M9'<#Y1[U]#_M:^./@+\4OV7KGP9X?\?^'Y=6\/VT=SH427(#&6%<>6./XTW+ MCU8?6@$?<'@GQ?IGC_PCH_B31KA;K2]5M([RVE4YRCJ&'XC.".Q!K\H?^"AO MAFW\9?MS:+H5R[0P:G;:?:22Q@%D5W921GOS7O/_ 29^.:^(?A_J_PQU"8F M_P!!D-]IP=N7M)6^9!_N2$_A(/2OG_\ X*.:]=^%_P!M73M9T^!+J_T^RL+F M"!U++(ZLQ52!R02.W- 6U/H%?^"/G@!E!_X3/7^?^FGOBMR_\ ^"K?QKT=8_M_ M@7PW8!^$-U87L6['7&Z49JY^S9\!OBA^V!\=M+^-WQ&8V?AJ.:*_@NN$%VL3 MGRK>VC!RL:L#EF]S\Q;- >IJ_P#!86#[1XU^&D84,[VERB@^ID4"JG_!/#]I MC4/@UXYF^"WC]GTZPN;@IITEV=OV.Z//E,QZ(_&WMD^]:'_!7K_D?OA=_P!< M)O\ T\M512)$4?\M(^O MNH/H* Z&A_P4I_:TF\&Z4/A+X-NGD\4:Q&HU.6T),EI ^-L0 _CE![-PG*D=B*]O_P""=7[+>H_%'Q5) M\)_9C_ .4EVO?]AC4_ M_0C0'D=Y^WK\?/%_QB^-5G\ _A].\=N]S':7AMY=AN[EOF*,P/$<8!)'L:]( M\#?\$D?AUI_ARWC\4:UJVKZVPW3W%I-]GB#8Y"J.P.>3DUX;\'KRUTG_ (*J MZS_:3I!YVJZE##YRXW2M&2@'N0#@U^L0.:!/0_(+X^_L_>,?^">WC[1?'OP_ MURYNO#:\$\&6=Q M:?\ !(KQ+Y\+Q>;YDL>\8W(;Z,AA[&@#YU_8B_:CU/\ 9B\=6QU-9S\/_$$H MAOU9&*1LAP9XNQ9-PW =01GM7Z6_MOZO8^(OV-?&^IZ=(?#VM64=]I.HZI=V]S;R#(=& !^A]#VKYI\&7FN_P#! M-W]K^72M4,LO@S4R(Y)L?+>:<[GRY@.GF1-P?H>S"OJ__@DS_P FW7__ &&[ MG^E=U_P4$^ 6E?&CX#ZOJ4OEVNO^%K>;5-/O6'("+NEB/^RZKCZA3VH#J>3? M\%*/VL(O#'@>R^'O@^_%QK/B6W2:YN+1LM%9OC:!CG,F>/;-=Y_P3R_90C^ MWPY7Q'KEE&GC37XUEG) +6L!&4A!_4^Y]J^-_P#@FA\"K'XU_%:Y\6^)9WO[ M'PK'%);V=P2YEF/^JR2>%0#('3I7[! 8 H$]!:***!'R]_P4GM9[W]D?Q7% M;0R7$IGL\1Q(68_Z0G85S?\ P2RLKBP_9J:*ZMY;:7^U;@[)D*-CCL:^I_%_ MB;0_"FD&\\0W,%KIY<(7N$W*6/08P:Y_P]\8OA_JERMEI7B#3EE8_+$O[H,? M;( S7-/$T*<_9SFE+LVKDNI%>ZV<7^W!!+=?LF?%"*&)YI6T>0+'&I9F.Y>@ M'6OA7]ASXB7WP*_9A^-_B)]+OFU(7-K#86WV=]\L[Q2*F!C. 2"3VK]3=8OK M*PTFZO-1>--/AB:29Y!N0(!DDCN*H^';C0?$NAV^HZ0EK=:9=#S(Y8H@$DP2 M,XQZ@BMN>/-R7UWL5=;'Y6_L5?L'VO[1.A^(?%GQ(?6-.MGNC':+ WDRSR$E MI9&WJ>,FOI?_ (=,?!O_ *"/B;_P-C_^-U]9>)/'7AGP!;Q?VQJEGI,;_^'O&\3R:%JUMJ2I]X0O\R_53R*R^L4O:>RYUS=KZ_<3SKF MY;ZGY/Z]\/-9_8'_ &T-&OO#UEJ>K>$F\N6*41&5Y;*4;)HW91C7%A(-)E6XC@TA'S3W6W:OMD_RKF_#?Q-\">--32UTG5].O[X ;(PN'(']W>"W9C\EW"0#\C?Q*/KC M(.?U8+!$)8@*!DD]!7 :G\8OAU%JOV&]\0:6]ZI\O#X< ^F[! _.BI7I4;>U MDHW[NP.48_$SX'_X*RVMQKWC+X576G6MQ?6[VLD@DMX6<;6D0@G XR/6OTD\ M*K_Q2VCJPY^Q0@@C_8%6%M=/U6W@G\FVO(2H,3[5==IZ;3Z?2LW2?&^A:QK] M_H=CJ$5QJE@/])M4!W1#..>,5;J0BTF]]O,&UL;EO;Q6D$<,$20PQ@*D<:A5 M4=@ .@K\FOV9]'OX/^"DNO7,EA=1VYU?4R)GA8(06./F(Q7ZD^+O'>@^!;:" MXU[4HM-@G?RXWE!(9L9QP#7')\=?A=#.9TU_34F/)E6%@WOSMS7/4QF'I2Y* ME1)]FT2ZD(NS9\C?\% ?V-_$VM^+HOC%\,1(;-EQ"1R6 M&!D>WUKA_!O_ 5.^(?A71_[)\9?#6;5]:M(EB-W LENTC@#Q[]* M_3*;7;'U>2Y1=.2 W#7!SM$8&=WKC'-9'AS4/"OCVP;5M*6PU:W>0HURL M*DEQU!R,YZ=:W]I#F4;J[UMY%\RV/RFU&S^./_!2#X@:2FIZ3+X>\'V;YWB) MX[.T4\.X+8,DA&0*^V_VM/AU9^ ?V#_%?@_P]9NUKIVF6MM!# A9WVW$63@= M2>2:^AO#_B70M4O=0TK2+F![C37\NYMH$VB%CS@C 'Y5:\1ZWI.@:9)=:S=V MUE8CAGNF 4]\<]3QTH]K#EY[JW<7,K7/DO\ X)3:==Z7^S!=0WMK-9S'Q%>M MY=Q&4;&R'!P>U8O_ 49_8[_ .%LZ!)\0O"=F7\7Z5#BZM80 ;ZW7DGW=1T] M1Q7UAX/^)_@SQ7=-8^']:L;FE4A[2$DX][Z"4TUS)GR%_P2FTZ[TO]G.^AO;6>SE.M7!\ MNXC*-CCG!KZ,_:)A>X^ WQ"CBC:65]!O55$&68^2W '>H(/C]\-;9-L/B2QB M7.2J1LH_1:[?0=>TWQ;HL&I:9<1W^FW*GRY5'RN 2IX/N"*SI8JA7?+2FI/R M:8HSC)^Z[GYX_P#!(#1M0TF'Q_\ ;K"YLMXMMOVB%H]W!Z9%?I#7$Z[\4O W M@74&L=1UK3]-NS]Z%1\P_P![:./QKI]%US3_ !#81WNF7D-]:2?=F@<,I_$5 MI&O2G-TXR3:W5]1\\9.R9H44F:*VN4>%_MB?\DE7T^WPY'XFOGKQIXK^&]]X M)6RT;P1>Z3X@*1A-2E C0.,;FR&)(//:OIK]J'POJWBWX;K9:-82ZC=B\BD\ MF 9;:""2]QRN]=$_LOS/'Q$+U)>BZ7_X8]1UXR']G>_\ -NTOI?[!;=<1L&60 M^5U!'6H_V;I/)^ OA>3&=EM(V/I*]1V7P_U'PQ^SS=>%@7O]472I80B'<6D9 M3\B^P)P*U/@+H5]X>^#OAS2]5M'L[V"!TFMYAAES(YP1]"*^CH0J?7:4Y1:_ M=6?D[QTN=D5+VL6U]G]4>/\ P1\)Z=\9_&OBOQAXHA&J26UZ;:UL[@;HXE&< M<=#@#TJ/XR^%]/\ @E\2?!GBSPO"-.%]>?9KNQ@^6*1Y?(.,<=< >PKYUTE]66%]F_K/->_*]^:_-S;6MY^5CCY?<]G;W[ M]O/>YM_M6>$]:\0:/H%[I^GRZSIFFW1FO]-@8[IDXP=HZ@8(]1G->67>O_#7 MQ_J.AVVG6C_M5^+KWPO\ M*([6SG>.XU29+-KB/'W-I+^_(&./6M30?V;O!5EX%CT6?2;>[N)8!YVH2IF9 MI2.7#=1ST [5J?%CX6GXA_#!O#L/;/7FO3Q7LJ.-E5QM-RC*"4='*SUYEI>S M>FIO4Y8U7*HKIK32_J>O_!_X?WGPS$IH=WK)UE8I6:&0Q[/+0]%')->4_!P M8_:;^)7^[_[/7HOP(\%Z[X,\&E/$E]/>:O=S-<2K-,9/)ST0$GCUXKD_A;X. MUO2/C_X]UF\TV>VTR]'^C73KA)?GSP?I6DZH>?)% N2%"]_KTJL/BSXY &/@[)I'@>49*P31N4W-QP?;NI]J^K?% M2ZCXG^$NKK_9TEOJE[I4JBPSEUD:,C9]<\5YE\-_@W-X@_9TC$^(["33M0\ MZXEB$RXD@D\QBCCTZ_D:]#,<-6KXZC5PUU*$&T^E[KW7ZJZL;5H2G5C*&Z7] M(L? EE;XL_%-E(*M>QD$="-M8OC'1?\ A:_[2T?AO66:Y\.Z/9"Y-EO*H[$# MJ._)Y]@*N_LL> O$G@C4/%2>(;&>W>1XTCGEY6;;D;E/<8Q5GXM^"/$_AKXG M:?\ $;PE8#6)4A^SWNG@_.ZXQD?ACIT(K%0JU,MI3J4W;GYI1MK;F;>G7TZD MV'PAJVGSHXNK*#&]!_#M!'/H?SK4_:+5 ME^"?B12VYA; %CW.1S7EVM>(OB#\?[C2](L/#U[X.TN"Z6:[U&25D<;1T!&# MW/ ZUZU\:O#=[JWP=UG1M,@FO[MK588HU^:23&!^)XKM3HU\/BI82DTI1WLU MS.SVB^W>VII[LX3=./3[].Q\R:#\0?@U::+90:C\/KV[OXX56>=43$CXY8?O M.]?6WPT_L>7X>:+)X>L#I6D7%J)K:T88,0?+8.">\/Z?I MA^$=U(#J>BWET)(M.>(QR6)Q]U@3 MUZ2LI+U MOW,J*M4BDN^ZU7SZGN^?\YHI<"BOT*YZP48I:* $Q1CBEHI@)@T$<4M% "8H MQ2T4 )BC%+12L F* *6BF F**6BD F#0.*6BF T@TN*6B@!, EX-101.SCH 5 hrmy-20240108.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 6 hrmy-20240108_lab.xml EX-101.LAB Document and Entity Information [Abstract] Amendment Flag Entity Central Index Key Document Type Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Adress Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity Emerging Growth Company EX-101.PRE 7 hrmy-20240108_pre.xml EX-101.PRE XML 8 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Jan. 08, 2024
Document and Entity Information [Abstract]
Amendment Flag	false
Entity Central Index Key	0001802665
Document Type	8-K
Document Period End Date	Jan. 08, 2024
Entity File Number	001-39450
Entity Registrant Name	HARMONY BIOSCIENCES HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-2279923
Entity Address, Address Line One	630 W. Germantown Pike
Entity Address, Adress Line Two	Suite 215
Entity Address, City or Town	Plymouth Meeting
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19462
City Area Code	484
Local Phone Number	539-9800
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.00001 par value per share
Trading Symbol	HRMY
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 9 hrmy-20240108x8k_htm.xml IDEA: XBRL DOCUMENT 0001802665 2024-01-08 2024-01-08 0001802665 false 8-K 2024-01-08 HARMONY BIOSCIENCES HOLDINGS, INC. DE 001-39450 82-2279923 630 W. Germantown Pike Suite 215 Plymouth Meeting PA 19462 484 539-9800 false false false false Common Stock, $0.00001 par value per share HRMY NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X9 M9K>]9!:GH_ 0 / ( \ !X;"]W M;W)K8F]O:RYX;6R-49:EL@9OTDUL(,BDBN0- M2TN'+#4$QJ8:@+W+IGD^R[S!H)>+D6M#V743&4K&& 3L@!W".?W.NU:=,.$> M'?)WH?NW ZT\!O1X 5OH7*M4Q_-+)+S$P,9M2XK.%7HR#'9 C.4?>-N)_#3[ MU"-L]A]&A!1ZE@MAA92XW^CYC6@\@2P/73>TFH M=>Y!L/?P&HT=S8\?M_P!4$L#!!0 ( ,5#*%@D'INBK0 /@! : M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q= M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*'3^ 5!+ P04 " #%0RA899!YDAD! #/ P M$P %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M= M< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4' M3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!- MFI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXP MC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T, M:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0 ( M ,5#*%@'04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ Q4,H6!2@:W_M *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ Q4,H6)E&PO=V]R:W-H965T&UL4$L! A0#% @ Q4,H6)^@&_"Q M @ X@P T ( !S P 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ Q4,H6"0>FZ*M M^ $ !H ( !_1$ 'AL+U]R96QS+W=O9(9 0 SP, !, ( ! MXA( %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& D "0 ^ @ +!0 end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports hrmy-20240108.xsd hrmy-20240108_lab.xml hrmy-20240108_pre.xml hrmy-20240108x8k.htm hrmy-20240108x8k001.jpg http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "hrmy-20240108x8k.htm": { "nsprefix": "hrmy", "nsuri": "http://www.harmonybiosciences.com/20240108", "dts": { "schema": { "local": [ "hrmy-20240108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "hrmy-20240108_lab.xml" ] }, "presentationLink": { "local": [ "hrmy-20240108_pre.xml" ] }, "inline": { "local": [ "hrmy-20240108x8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_8_2024_To_1_8_2024_GCLp4aSY6UuGEfHSHmm4cQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240108x8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_8_2024_To_1_8_2024_GCLp4aSY6UuGEfHSHmm4cQ", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "hrmy-20240108x8k.htm", "first": true, "unique": true } } }, "tag": { "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Adress Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.harmonybiosciences.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001558370-24-000128-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-24-000128-xbrl.zip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end